More Than 200 Patient Advocates, Healthcare Entities, Companies Urge Finalized Pharmacy DIR Fee Transparency Rule That Would Promote Patient Access, Protect Pharmacy Viability Groups applaud CMS’ ongoing efforts to address DIR fees; urge further action for comprehensive pharmacy DIR reform that “reduce[s] [Medicare] beneficiary drug costs and also protect[s] pharmacy access”
Groups applaud CMS’ ongoing efforts to address DIR fees; urge further action for comprehensive pharmacy DIR reform that “reduce[s] [Medicare] beneficiary drug costs and also protect[s] pharmacy access”.